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AbstrACt
Objectives Depressive symptoms are common but rarely 
considered a risk factor for unhealthy lifestyles associated 
with cardiovascular disease (CVD). This study investigates 
whether depressive symptoms are associated with 
reduced physical activity (PA) in individuals at high risk of 
developing CVD.
Design Secondary analysis of the cross-sectional 
baseline data from a randomised controlled trial of an 
intensive lifestyle intervention.
setting 135 primary care practices in South London, UK.
Participants 1742 adults, 49–74 years, 86% male at 
high (≥20%) risk of developing CVD in the next 10 years as 
defined via QRISK2 score.
Outcome measures The main explanatory variable was 
depressive symptoms measured via the Patient Health 
Questionnaire-9 (PHQ-9). The main outcome was daily 
step count measured with an accelerometer (ActiGraph 
GT3X) stratified by weekdays and weekend days.
results The median daily step count of the total sample 
was 6151 (IQR 3510) with significant differences (P<0.001) 
in mean daily step count between participants with low 
(PHQ-9 score: 0–4), mild (PHQ-9 score: 5–9) and moderate to 
severe depressive symptoms (PHQ-9 score: ≥10). Controlling 
for age, gender, ethnicity, education level, body mass index 
(BMI), smoking, consumption of alcohol, day of the week 
and season, individuals with mild depressive symptoms and 
those with moderate to severe depressive symptoms walked 
13.3% (95% CI 18.8% to 7.9%) and 15.6% (95% CI 23.7% 
to 6.5%) less than non-depressed individuals, respectively. 
Furthermore, male gender, white ethnicity, higher education 
level, lower BMI, non-smoking, moderate alcohol intake, 
weekdays and summer season were independently 
associated with higher step count.
Conclusions People at high risk of CVD with depressive 
symptoms have lower levels of PA.
trial registration ISRCTN84864870; Pre-results.
IntrODuCtIOn 
Cardiovascular disease (CVD) remains the 
most common cause of death worldwide: 
it accounts for a third of global mortality1 
and contributes considerably to years lost 
to disability.2 The main lifestyle risk factors 
for CVD are tobacco smoking, physical inac-
tivity, unhealthy diets and the harmful use of 
alcohol.1 Estimations suggest that increasing 
physical activity (PA) to the WHO recom-
mended amount would reduce the global 
CVD-related burden by 6%.3 It is increasingly 
recognised that depression (defined here 
as an umbrella term for depressive disorder 
and depressive symptoms) is an independent 
risk factor for CVD4 and is associated with 
increased risk of mortality after a CVD event,5 
but mental health is not routinely considered 
as a factor that may affect uptake of PA to 
improve CVD outcomes in clinical practice or 
intervention studies.
strengths and limitations of this study
 ► This study is the first to look at the relationship be-
tween depressive symptoms and objectively mea-
sured physical activity in a large sample (n=1720) of 
individuals at high risk of developing cardiovascular 
disease.
 ► The analysis controls for potential confounding of: 
age, gender, ethnicity, education level, body mass 
index, smoking, consumption of alcohol, day of the 
week and season.
 ► The inclusion of participants with as little as one val-
id wear day tries to minimise bias by not excluding 
more depressed participants that did not wear the 
monitor for the requested 5 days.
 ► No causalities can be inferred from the cross-sec-
tional data.
 ► As it is a sample from the general population, the 
proportion of severely depressed subjects is small, 
and the power to compare the severity categories of 
depressive symptoms on step count is limited.
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For most individuals and especially the elderly, the most 
accessible and safest form of PA is walking. Increased 
number of daily steps, independent of walking speed 
or intensity, is associated with improved biomedical 
outcomes such as lower body mass index (BMI),6 lower 
cholesterol ratio and triglyceride levels7 and a lower rate 
of CVD incidents overall.8 Self-report questionnaires to 
assess walking are prone to over-reporting and under-re-
porting biases.9 Using objective tools to assess walking, 
such as accelerometers or pedometers, can overcome 
this limitation.10 Potential confounders of any associa-
tion between depressive symptoms and walking include 
younger age, male gender, lower BMI and white ethnicity, 
which are associated with higher step count.11–14 Educa-
tion is also a potential confounder, although there have 
been mixed findings.11 12 15 There are also well known 
time effects, namely that people walk more on weekdays 
than on weekends and during summer months than in 
winter.14
The relationship between depressive symptoms and 
step count has only been assessed in specific populations 
with small sample sizes, such as low-socioeconomic status 
Latino immigrants,16 elderly Japanese people17 or patients 
with chronic conditions such as heart failure18 19 or 
chronic obstructive pulmonary disease.20 21 Studies yield 
contradictory results, with some observing no association 
between depressive symptoms and daily step count,19 21 
while others report a negative correlation.16–18 20 In one 
cross-sectional sample of healthy older adults, an inverse 
association between depressive symptoms (using the Gold-
berg Depression Scale-15) and accelerometer measured 
daily step count disappeared after controlling for general 
health and disability.22 While a systematic review suggests 
reduced levels of objectively measured PA in patients with 
depression,23 it is not known whether this association 
is present in those at high risk of CVD and taken into 
account important confounding such as gender and age.
We aim to describe the distribution of objectively 
measured average daily step count in a sample at high risk 
of CVD and to test the hypothesis that individuals with 
greater depressive symptoms are likely to have reduced 
daily step counts, controlling for potential confounding.
MAterIAls AnD MethODs
Design
This is a cross-sectional analysis of the baseline data of 
individuals at high risk of CVD, who were participating in 
a randomised controlled trial (RCT) testing the effective-
ness of an intensive lifestyle intervention ‘MOtiVational 
intErviewing InTervention’ (MOVE IT) to increase PA 
and reduce weight. The data were collected before partic-
ipants were randomised.
setting and sampling frame
The MOVE IT study was conducted in the 12 South 
London Clinical Commissioning Groups (CCGs), which 
are the local administrative authorities for commissioning 
healthcare for its residents, representing a diverse socio-
economic and ethnic population of approximately 3 
million UK residents. All primary care practices with a 
list size of >5000 registered patients resident within these 
CCGs were invited to participate. Within these practices, 
patients with a ≥20% risk of having a fatal or non-fatal 
CVD event in the next 10 years as defined by the QRISK2 
score (2013 version),24 were identified from the practice 
register. The QRISK2 score is a validated predictive tool 
for identifying individuals at risk of developing a fatal or 
non-fatal cardiovascular event in the next 10 years based 
on age, smoking status, ethnicity, systolic blood pressure, 
ratio of total serum cholesterol to high-density lipopro-
tein cholesterol, BMI, family history of coronary heart 
disease in first-degree relative, Townsend deprivation 
score, treated hypertension and diagnosis of rheuma-
toid arthritis.24 Further patient inclusion criteria were: 
age ≥40 and ≤74 years, permanent residency and fluent 
in English. The exclusion criteria were: known CVD; 
on the general practice electronic register for diabetes, 
chronic kidney disease, atrial fibrillation or stroke; and 
chronic obstructive pulmonary disease or morbid obesity 
(BMI >50 kg/m2). Participants were recruited from 7 June 
2013 to 19 February 2015. All participants gave written 
informed consent. Further details of the trial protocol are 
available.25
Measures
The main explanatory variable was self-report depres-
sive symptoms using the Patient Health Questionnaire-9 
(PHQ-9).26 The PHQ-9 scores the occurrence of each of 
the nine Diagnostic and Statistical Manual of Mental Disor-
ders, 4th Edition criteria for major depressive disorder 
over the past 2  weeks on a scale from 0 (not at all) to 3 
(nearly every day). The total sum score, ranging from 0 to 
27, can be categorised as not depressed (0–4), mild (5–9), 
moderate (10–14), moderately severe (15–19) and severe 
depression (20–27).26 A score of 10 or above is defined 
as clinically relevant depression and a recent meta-anal-
ysis reported that a cut-off score ≥10 generated a sensi-
tivity of 77% and specificity of 85% in diagnosis for major 
depression.27 In our study, the number of individuals 
with scores in the three top categories (10–14, 15–19 and 
20–27) was low (2.9, 0.9 and 0.2%, respectively); there-
fore, we merged them to create one category of moderate 
to severe ‘clinical’ depression (score ≥10).
The main outcome was the average daily number of 
steps measured with the ActiGraph GT3X accelerometer 
(ActiGraph, Florida, USA), a triaxial movement sensor 
that has been validated on number of steps taken and 
is reported to record 98.5% of steps.28 Number of steps 
correlated (r=0.70) with average moderate-to-vigorous 
physical activity (MVPA). We chose steps per day as the 
main outcome measure in this analysis as it was specified 
as the main outcome measure in the MOVE IT trial, and 
walking is the main form of PA in this elderly population. 
We also note that steps per day was highly correlated with 
minutes of MVPA (r=0.75). Steps also has the merit that it 
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is an easily understood measure that facilitates clinical 
application of the results. The accelerometers were given 
to the participants by a researcher who advised them to 
attach the monitor to the waist and wear it for 7 days from 
waking in the morning until going to bed at night, only 
removing it for bathing and swimming. If monitors were 
worn for less than 9 hours (540 min) per day, these wear 
days were considered missing as it suggests the partici-
pant forgot to wear the monitor for a part of the day. The 
aim was to generate a minimum of five valid wear days 
per participant to ensure the collected data represent 
habitual activity levels.29 A preliminary analysis revealed 
that people who wore the monitor for less than 5 days 
exhibited significantly more depressive symptoms than 
those who wore it for at least 5 days, so to reduce bias, 
we included individuals who had less than 5 days of wear 
time. We therefore included all participants with at least 
one valid wear day in the analysis and performed a sensi-
tivity analysis to determine whether including individuals 
with one wear day only altered the results.
To account for potential confounding, reported covari-
ates of depressive symptoms and objectively measured 
PA (age, gender, BMI, ethnicity, day of the week, level of 
education,11 season14 smoking and alcohol intake30) were 
controlled for in the analysis. During the one-on-one 
interview with the researcher, participants reported age, 
gender and ethnicity and were weighed and measured 
with standardised scales.25 Self-reported levels of educa-
tional attainment were categorised into: level 1: no formal 
qualifications; level 2: qualifications at the end of compul-
sory school education in the UK typically at age 16 years; 
or level 3: qualifications awarded at the end of further 
education typically at age 18 years. Reported smoking 
status was categorised as: never smoked, ex-smoker and 
current smoker. The Alcohol Use Disorders Identification 
Test (AUDIT), a 10-item structured questionnaire that 
categorises alcohol consumption, grouped participants 
into abstainers (AUDIT score=0), low risk (score 1–7) 
and possibly hazardous or harmful drinkers (score ≥8).31
statistical analysis
Data on daily step count were downloaded from the 
activity monitors using Actilife V.6.11.7.32 The number 
of valid wear days (≥540 min) per participant was 
counted. Extreme outliers in daily step count were 
individually investigated to ensure plausibility and rule 
out device failure. This was not the case and no cases 
were removed from the analysis. Measurements of step 
count were divided into weekdays (Monday–Friday) 
and weekend days (Saturday and Sunday). Within these 
categories, the arithmetic mean of the step count for 
each participant was calculated, thereby creating at 
least one and at most two measurements per partic-
ipant. Baseline characteristics were summarised as 
means (±SD) or percentages. As the step count data 
were not normally distributed, median and its IQR are 
presented, and non-parametric Spearman rank correla-
tions were applied. To identify relevant confounders 
of step count, Mann-Whitney U and Kruskall Wallis 
tests were conducted to compare differences between 
categories of potential confounders. No adjustments 
for multiple testing were made in order avoid missing 
potentially important confounders due to an inflation 
of the type II error for our final model.33
For the main analysis, a linear mixed model (LMM) was 
used. LMMs can account for the dependency of repeated 
observations of the same subject (weekdays and week-
ends) and allow including all individuals with at least one 
outcome observation.34 To improve the fit of the model, 
the step count data were log-transformed before they were 
entered into the model. In order to investigate the sizes 
of the adjusted and unadjusted effects of each predictor 
on step count, we introduced two models. The first model 
aims to describe the individual associations between each 
predictor and mean daily step count. We controlled for 
age, gender, season and day of accelerometer wear (basic 
confounders) and then individually entered each addi-
tional covariate: (a) depressive symptoms, (b) ethnicity, 
(c) education level, (d) BMI, (e) smoking status and 
(f) drinking of alcohol into the LMM as independent 
predictor for log step count, obtaining the estimated 
change caused by each of the predictors. In the second 
model, all variables were entered simultaneously to deter-
mine the mutually adjusted effects of all predictors. Age 
and BMI were entered as continuous fixed effects vari-
ables (centred around the mean), and the others were 
entered as categorical fixed effects variables. We used an 
unstructured covariance structure for the LMM. Assump-
tions of the LMM were assessed by visual inspection of 
the residual plots.35 Controlling for nesting at practice 
level showed that the estimated variance was virtually 0, 
thus practice level was excluded from the final LMM. The 
constant for each LMM is reported alongside the coef-
ficients of relative change for each variable. These rela-
tive differences between the log transformed step counts 
were back transformed to the percentage difference in 
step count by applying the formula 100(eCoefficient−1). To 
account for multiple testing in the final LMM, the alpha-
level is lowered to α=0.01, and predictors with p values 
<0.05 but >0.01 are treated as trend and interpreted with 
caution.36
A sensitivity analysis was conducted to determine if 
wearing the accelerometer for less than 5 days alters the 
results by rerunning the main analyses on participants 
with at least five wear days (online supplementary table 
1). Reanalysis of QRISK2 scores using cleaned data and 
the QRISK2 2013 batch calculator revealed that 155 (9%) 
of the included participants had a QRISK2 score <20%. 
We conducted a second sensitivity analysis by rerun-
ning the main analyses including only patients with a 
QRISK2 score of ≥20 (online supplementary table 2) to 
check for potential bias. Independent sample t-tests were 
used to compare depression scores between subsamples 
(≥5 vs <5 wear days and ≥20% and <20% QRISK2). Data 
were analysed using IBM SPSS Statistics for Macintosh, 
V.24.0 was used for all analyses.
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results
Population characteristics
The MOVE IT sample consisted of 135 primary care prac-
tices in the 12 South London CCGs, from which 1742 
participants were eligible on screening and consented 
to participate. Only n=22 (1.3%) provided less than one 
valid wear day with ≥540 min and had to be excluded 
right away. Additionally, 117 participants (6.7%) provided 
at least one but less than the requested five full wear days. 
When comparing these 117 participants with those who 
wore the monitor for 5 days or more, we found that the 
former were significantly more depressed than the latter 
(P<0.001). If we excluded this group, this may lead to an 
underestimation of the effect of depression on step count; 
therefore, we decided to include this group, giving a final 
sample of 1720. The average QRISK2 score of the sample 
was 25% (SD 4.9). On recalculation of QRISK2 scores, 155 
patients with a score <20% had been recruited into the 
trial. As there was no difference in depressive symptoms 
compared with those with QRISK2 score ≥20% (P=0.394), 
we retained this subgroup in the analysis. The mean age 
was 69 (SD 4.1) years, the vast majority were male and of 
white ethnicity. Demographic and behavioural character-
istics of the final sample stratified by accelerometer wear 
day are reported in table 1.
step count data
A total of 11 140 wear days from n=1720 participants were 
included in the analysis. These participants provided a 
mean of 6.5 (SD 1.2) wear days. Daily step count ranged 
from 105 to 21 313 steps with a median of 6151 (IQR 3510). 
Figure 1 shows an inverse relationship (Spearman’s rho 
Table 1 Demographic characteristics and distribution of median daily step count in a randomised controlled trial assessing 
the effectiveness of an intensive lifestyle intervention
Variables 
Weekdays Weekends
N (%)
Median steps 
(IQR)* P values† N (%)
Median steps 
(IQR)* P values†
Total study population 1719 (100) 6447 (3875) 1645 (100) 5676 (3737)
Age >70 58 (3.4) 6434 (4175) P=0.859 52 (3.2) 5639 (4209) P=0.454
50–59‡ 701 (40.8) 6319 (4017) 661 (40.2) 5784 (3985)
60–69 960 (55.8) 6485 (3738) 932 (56.7) 5640 (3659)
Gender Male 1470 (85.5) 6665 (3910) P<0.001 1402 (85.2) 5903 (3870) P<0.001
Female 249 (14.5) 5441 (3343) 243 (14.8) 4590 (3143)
Ethnicity White 1538 (89.5) 6536 (3895) P<0.001 1472 (89.5) 5800 (3757) P<0.001
Black/Asian/other 181 (10.5) 5619 (3493) 173 (10.5) 4676 (3321)
Education level§ Level1 427 (25.3) 6022 (3742) P=0.001 399 (24.7) 5287 (3713) P=0.018
Level 2 467 (27.6) 6391 (4070) 444 (27.5) 5517 (3907)
Level 3 796 (47.1) 6734 (3871) 774 (47.9) 5928 (3690)
Depressive  None (0–4) 1449 (84.3) 6656 (3855) P<0.001 1394 (84.7) 5804 (3831) P<0.001
symptoms Mild (5-9) 201 (11.7) 5563 (3330) 189 (11.5) 5045 (3473)
(PHQ-9) Moderate/severe 
(≥10)
69 (4.0) 5428 (3905) 62 (3.8) 5258 (3939)
BMI (kg/m2) <20 24 (1.4) 6899 (4774) P<0.001 22 (1.3) 6178 (3899) P<0.001
20–24.9 371 (21.6) 7255 (3983) 365 (22.2) 6307 (4329)
25–29.9 800 (46.5) 6550 (3736) 773 (47.0) 5796 (3615)
≥30 524 (30.5) 5850 (3594) 485 (29.5) 5108 (3559)
Smoking status Never smoked 482 (28.0) 6485 (3694) P<0.001 468 (28.4) 5795 (3760) P=0.047
Ex-smoker 975 (56.7) 6605 (3850) 929 (56.5) 5784 (3670)
Current smoker 262 (15.2) 5795 (4285) 248 (15.1) 5268 (4115)
Alcohol intake Abstainer (0) 176 (10.2) 5533 (4208) P<0.001 171 (10.4) 4984 (3598) P=0.001
(AUDIT) Low risk (1-7) 1274 (74.2) 6544 (3628) 1216 (73.9) 5767 (3629)
Harmful (≥8) 269 (15.6) 6490 (4370) 258 (15.7) 5787 (4027)
*Median step count and IQR are rounded to the closest full number. 
†P values are calculated with Mann-Whitney U tests and Kruskall-Wallis tests.
‡One person was younger than 50 years (49); this person was included in the ≥50 category. 
§n=29 missing for weekdays; n=28 missing for weekends.
AUDIT, Alcohol Use Disorders Identification; BMI, body mass index; PHQ-9, Patient Health Questionnaire-9.
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r=−0.149, P=0.01) between depressive symptom score and 
mean individual daily step count. Step count also differs 
between categories of gender, ethnicity, education level, 
BMI, smoking, drinking of alcohol and with weekdays, 
but not age (table 1).
linear mixed model
The LMMs (table 2) observed significant associa-
tions between depressive symptoms and step count. 
Controlling for age, gender day and season (model 1), 
individuals with moderate to severe depressive symptoms 
walked 19.0% less (P<0.001) than non-depressed indi-
viduals, and mildly depressed individuals walked 16.2% 
less (P<0.001). Mutually controlling for all predictors 
(model 2) decreased the effect of depressive symptoms 
to 15.6% and 13.5%, respectively (P=0.001 and P<0.001). 
All other covariates influenced PA as well. In model 2, 
each additional year in age and one point increase in BMI 
was associated with a decrease in step count by 1.2% and 
2.7%, respectively (P<0.001 and P<0.001). Female gender 
reduced step count by 13.8% (P<0.001); individuals from 
ethnic minorities walked 17.8% less steps (P<0.001). 
Higher educational qualifications tended to be associated 
with higher step count. Subjects with level 3 qualifica-
tions walked 5.3% more than level 2 (P=0.028) and 5.7% 
more than those without formal qualification (P=0.022). 
Current smokers’ step count was 19.1% lower compared 
with people who had never smoked (P<0.001), and partic-
ipants abstaining from alcohol consumption had an 8.8% 
lower step count than people who are low risk drinkers 
(P=0.01). On weekends, 14.8% fewer steps were recorded 
than on weekdays (P<0.001), and during the winter 
months, there was a decrease of 9.3% compared with 
spring (P=0.001). Sensitivity analyses revealed that rerun-
ning the models with participants with at least 5 days of 
complete wear time (online supplementary table 1) and 
participants with QRISK2 score >20 only (online supple-
mentary table 2) provided similar parameter estimates 
and did not alter the conclusions of this study.
DIsCussIOn
Main study findings
This study assessed patterns of PA and depressive symp-
toms in people at high risk of CVD. We found an inverse 
relationship where increased depressive symptoms were 
associated with significantly decreased step counts. 
Female gender, ethnic minorities, lower education level, 
higher BMI, smoking, alcohol abstainers, weekends and 
colder season were independently associated with lower 
daily step count.
study strengths and limitations
The strengths of our study are, first, the large sample 
size. Furthermore, PA was objectively assessed based on 
accelerometer data. Sociodemographic, biomedical 
and depression data were collected in face-to-face inter-
views with trained researchers using standardised sched-
ules, resulting in very few missing data. Recruitment 
was conducted year-round so seasonal variations were 
accounted for.
Figure 1 The association between depressive symptoms and daily step count at baseline in adults with high cardiovascular 
risk in a randomised controlled trial assessing the effectiveness of an intensive lifestyle intervention to improve physical activity 
and reduce weight.
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Table 2 Estimated effects (coefficients and relative % change) of individual characteristics on average daily steps in subjects 
at high risk of CVD 
Variables
Model 1† Model 2‡
Coefficient
Relative %
Change (95% CI) Coefficient
Relative %
Change (95% CI) 
Constant 8.813 8.937
Basic confounders
  Age (impact additional year) 0.004 0.4 (−0.1 to 1.0) −0.012*** −1.2 (−1.7 to −0.6)
  Gender 
   Male 0 0 0 0
   Female −0.249*** −22.1 (−26.7 to −17.2) −0.149*** −13.8 (−18.9 to −8.5)
  Day 
   Weekday 0 0 0 0
   Weekend −0.161*** −14.9 (−16.6 to −13.2) −0.161*** −14.9 (−16.6 to −13.1)
  Season 
   Spring 0 0 0 0
   Summer −0.007 −0.7 (−6.7 to 5.7) 0.004 0.4 (−5.4 to 6.7)
   Autumn −0.013 −1.3 (−7.2 to 5.0) −0.015 −1.5 (−7.2 to 4.5)
   Winter −0.086** −8.3 (−13.8 to −2.4) −0.098** −9.3 (−14.5 to −3.8)
Added covariates
  a) Depressive symptoms constant 8.84
   None (PHQ-9: 0–4) 0 0 0 0
   Mild (PHQ-9: 5–9) −0.177*** −16.2 (−21.5 to −10.6) −0.142*** −13.3 (−18.6 to −7.6)
   Moderate/Severe (PHQ-9 ≥ 10) −0.211*** −19.0 (−27.2 to −10.0) −0.170** −15.6 (−23.8 to −6.6)
  b) Ethnicity constant 8.845
   White 0 0 0 0
   Black/Asian/other −0.145*** −13.5 (−19.2 to −7.4) −0.196*** −17.8 (−23.3 to −12.0)
  c) Education level constant 8.845
   Level 3: A Level or higher 0 0 0 0
   Level 2: O Level/GCSE/NVQ −0.063* −6.1 (−10.7 to −1.2) −0.054* −5.3 (−9.7 to −0.6)
   Level 1: no formal qualification −0.072** −7.0 (−11.7 to −2.0) −0.196* −5.7 (−10.4 to −0.9)
  d) BMI constant 8.811
   Impact of one unit BMI increase −0.025*** −2.4 (−2.9 to −1.9) −0.027*** −2.7 (−3.2 to −2.2)
  e) Smoking status constant 8.849
   Never smoked 0 0 0 0
   Ex-smoker −0.023 −2.3 (−6.9 to −2.5) −0.038 −3.7 (−8.2 to 0.9)
   Current smoker −0.141*** −13.2 (−18.9 to −7.0) −0.212*** −19.1 (−24.4 to −13.4)
  f) AUDIT score constant 8.824
   Low risk (score 1 – 7) 0 0 0 0
   Possibly harmful (score ≥ 8) −0.001 −0.1 (−5.8 to 6.0) 0.032 3.3 (−2.4 to 9.3)
   Abstainer (score 0) −0.124** −11.7 (−17.6 to −5.2) −0.092* −8.8 (−14.9 to −2.2)
Significance levels: *P<0.05, **P<0.01 and ***P<0.001.
†Model 1: all variables (a-f) adjusted for basic confounders (age, gender, day and season) only. Note: there is a constant for the basic 
confounders only model and separate constants for this model adjusted for each added covariate (a–f).
‡Model 2: all variables are mutually adjusted; thus, there is only one constant for the whole model.
The reference group within each category is set to 0.
AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index; CVD, cardiovascular disease; GCSE, General Certificate of 
Secondary Education; NVQ, National Vocational Qualification; PHQ-9, Patient Health Questionnaire-9.
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The limitations are that the study design is cross-sec-
tional, so causal relationships cannot be inferred, and it 
remains unclear whether people with depressive symp-
toms are at increased risk of walking less or less active 
people are at increased risk for depressive symptoms. 
Although PA was measured objectively using acceler-
ometers, we cannot rule out that the recorded levels of 
PA are subject to bias, as participants might have changed 
their performance because they knew they were being 
observed.37 This would not, however, have biased esti-
mates of the association with depressive symptoms unless 
depressed individuals respond differently to wearing 
accelerometers. As this is the baseline sample of an RCT to 
improve CVD risk by increasing PA and reducing weight, 
there is the risk of a participation bias in our sample. The 
participants may be more interested in exercise than the 
general population, as they have consented in taking part 
in a behaviour change study. The percentage of female 
participants was small (14.5%), reflecting the lower 
QRISK2 sores in females.24 However, data on females with 
high CVD risk is relevant as the prevalence of depres-
sion is higher in females, and they have worse outcomes 
following CVD events.38
The number of study participants with severe depressive 
symptoms was small, which is to be expected in a primary 
care population. Our analysis showed that depressive 
symptom scores were significantly higher in individuals 
who failed to provide the requested five wear days. We 
tried to minimise any measurement bias by depression by 
including all participants with as little as one valid wear 
day. Finally, as in any study with missing outcome data, we 
cannot exclude potential bias if missing values do depend 
on unobserved values (not missing at random).39
Comparison with other studies
Normative data suggest that between 2000 and 9000 
daily steps are a typical estimate of usual daily activity 
levels in healthy older adults (≥50 years).13 Our sample 
falls into that range with an average of 6515 daily steps. 
The high inter-individual variability in step count, in our 
case an IQR of 3510, is also similar to findings in previous 
studies.11 12 15 Women seem to be especially likely to have 
a sedentary lifestyle, particularly on weekends. Ethnicity 
and BMI showed a significant influence on step count, 
as reported in previous studies.11 13 14 The role of educa-
tion level for PA continues to be uncertain with signifi-
cant differences in daily steps between education levels 
in model 1 but only trend level significance in model 2. 
Similarly, we found that individuals with moderate alcohol 
consumption walked more than abstainers (significant 
difference in model 1, trend level significance in model 
2), which has been reported previously in accelerometer 
and large population-based studies.40 41 One speculation 
is that these participants might be what is termed ‘social 
drinkers’ who are perhaps more likely to travel for a 
drink, for example to the pub, whereas abstainers might 
have an advanced disease or are socially isolated. These 
findings suggest prevention programmes to increase PA 
should be targeted at specific subgroups of people at high 
risk of CVD, as well as the general population.
The prevalence of clinically relevant depressive symp-
toms (PHQ-9 score ≥10) in our sample was 4%, which is 
midway between the reported UK prevalence of 2.8% in 
the general population (2.6% in males, 3.0% in females)38 
and 7% in patients with CVD.42 It is important to note 
that these statistics refer to current episodes of depres-
sive symptoms (within the past 2 weeks). Lifetime preva-
lence of depression in the UK is reported to be higher, at 
around 25.8%,43 and may also be associated with reduced 
PA to a greater or lesser extent, but the difference in PA 
levels between the two constructs of depressive symptoms 
have not yet been examined.
Our participants did not have CVD and were not on 
clinical primary care registers for other long-term condi-
tions. However, they were at high risk of developing 
CVD, and the prevalence rate of depressive symptoms 
was higher than in the general population. This is consis-
tent with the results of a recent Danish register study 
which reported that depression might be an antecedent 
for CVD events and mortality,44 further indicating the 
importance of depressive symptoms as an easily measured 
risk factor for CVD. Previous studies on the association 
between objectively measured PA and depression yielded 
inconclusive results. They have reported either a lack 
of a relationship,19 21 an inverse association16–18 20 or an 
inverse association that disappeared when controlled for 
confounding.22 The studies that reported negative asso-
ciations between daily step count and depressive symp-
toms have been conducted in relatively small (n=96 to 
n=207)17–19 22 or in highly selective samples such as severe 
COPD.20 Our study is the first to examine this relation-
ship in a large sample of community-dwelling older Euro-
pean adults at high risk of CVD who were not known to 
have a chronic disease.
Implications for clinicians
Practitioners and researchers should consider assessing 
depressive symptoms when assessing patients’ CVD risk 
or their barriers to uptake of lifestyle interventions. Even 
mild symptoms of depression (PHQ-9 scores 5–9) were 
associated with a significantly reduced average daily step 
count of 13.3%. Similarly, it has been shown that mild 
symptoms of depression increase mortality risk after 
acute myocardial infarction.45 A Cochrane review and a 
meta-meta-analysis on the effectiveness of PA interven-
tions for the treatment of depression in clinical46 and 
non-clinical samples47 summarised that there appeared to 
be a moderate positive effect of increased PA on depres-
sive symptoms. However, when stratified by quality of 
studies, the Cochrane review found no statistically signif-
icant evidence in methodologically robust RCTs that 
exercise was more effective than psychological or phar-
macological therapies.46 Nevertheless, we still found that 
depressive symptoms are associated with lower PA levels 
in individuals at high risk of CVD, which highlights the 
importance of screening and optimising conventional 
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depression management48 to reduce depressive symp-
toms, which could help lower CVD risk.3 4
Implications for future work
The varying patterns of PA in individuals at high risk of 
CVD indicate that it might be most efficient to target 
PA interventions specifically towards those with lowest 
activity ratings, for example, females, those from African, 
Caribbean or Asian ethnicities, those with higher BMIs 
or current smokers. Additionally, our results suggest that 
there is a moderate association between depressive symp-
toms and daily step count in individuals at high risk of 
CVD and that this should be considered as a potential 
modifying factor in clinical trials for lifestyle interven-
tions in CVD research.
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